MET and neoplasm: Comparative survival data are compiled in Fig. 6D. Immunohistochemical assessments of the mouse brains revealed reduced tumor volumes by trend, and a significant reduction in CD31-positive vessels in MET-deficient tumors relative to controls (Fig. 6E).